Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) EBITDA Margin (2016 - 2025)

Coherus Oncology (CHRS) has disclosed EBITDA Margin for 12 consecutive years, with 359.9% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 176991.0% to 359.9% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 429.51% through Dec 2025, down 25810.0% year-over-year, with the annual reading at 429.51% for FY2025, 25810.0% down from the prior year.
  • EBITDA Margin hit 359.9% in Q4 2025 for Coherus Oncology, up from 383.14% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1410.01% in Q4 2024 to a low of 2937.05% in Q1 2024.
  • Historically, EBITDA Margin has averaged 283.89% across 5 years, with a median of 155.86% in 2022.
  • Biggest five-year swings in EBITDA Margin: tumbled -272819bps in 2024 and later skyrocketed 233914bps in 2025.
  • Year by year, EBITDA Margin stood at 53.9% in 2021, then plummeted by -111bps to 113.54% in 2022, then surged by 34bps to 75.29% in 2023, then surged by 1973bps to 1410.01% in 2024, then tumbled by -126bps to 359.9% in 2025.
  • Business Quant data shows EBITDA Margin for CHRS at 359.9% in Q4 2025, 383.14% in Q3 2025, and 443.59% in Q2 2025.